【出版时间及名称】：2009年11月中国医药分销行业研究报告
        【作者】：摩根斯坦利
        【文件格式】：PDF
        【页数】：88
        【目录或简介】：
Contents
Investment Case............................................................................................................................................................. 3
Drug Distribution – A Long-Term Growth Industry .................................................................................................................................................. 3
Government Support is Boosting Growth................................................................................................................................................................ 3
Industry Consolidation Could Offer Further Upside................................................................................................................................................. 3
EDL Makes the Biggest Even Bigger ...................................................................................................................................................................... 3
Drug Distribution Industry Overview ............................................................................................................................ 4
Planned Economy Stage (1950–1984) ................................................................................................................................................................... 4
Transitioning Stage (1985–1989) ............................................................................................................................................................................ 4
Market-oriented Stage (1990–present) ................................................................................................................................................................... 5
Current Industry Landscape ......................................................................................................................................... 5
Pharmaceutical Sales in China ..................................................................................................................................... 6
Major Challenges of the Drug Distribution Industry.................................................................................................... 7
Future Trends: The Impact of Healthcare Reform ....................................................................................................... 8
Industry Regulations and Policies ............................................................................................................................... 9
Competitive Analysis ................................................................................................................................................... 10
Industry Players ........................................................................................................................................................... 12
Drug Distributors: Financial Comparisons................................................................................................................. 23
Company Analysis
Sinopharm Group: China Healthcare Proxy with Robust Growth but Upside Priced in for Now; Initiate EW .............. 27
Company Background
Overview ....................................................................................................................................................................... 66
Change in Shareholder Structure............................................................................................................................... 66
Pharmaceutical Distribution: Products & Services ................................................................................................... 72
Retail Business: A Meaningful Presence in China .................................................................................................... 76
Other Business Operations......................................................................................................................................... 76
Business Strategies – Organic Growth Complemented by M&A............................................................................. 77
Case Study: How did Sinopharm grow Organically and through Acquisitions? ................................................... 78